Maravai LifeSciences (MRVI) Tops Q4 EPS by 3c ; Offers Guidance

Maravai LifeSciences (NASDAQ: MRVI) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $49.02 million.

GUIDANCE:

Maravai LifeSciences sees FY2026 revenue of $200-210 million, versus the consensus of $203.3 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• AIG (AIG) call put ratio 4 calls to 1 put with a focus on June 26 weekly calls as share price up 3.9%